Also found in: Wikipedia.


name given to prostaglandin E2 when used pharmaceutically; used as an oxytocic for induction of abortion or of labor, to evacuate the uterus in the management of missed abortion, to aid ripening of the cervix prior to the induction of labor, and in the treatment of hydatidiform mole; administered intravaginally or intracervically.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

dinoprostone (prostaglandin E2, PGE2)

Cervidil Vaginal Insert, Prepidil Endocervical Gel, Propress (UK), Prostin E2 Vaginal Suppository

Pharmacologic class: Oxytocic, prostaglandin

Therapeutic class: Abortifacient, cervical ripening agent

Pregnancy risk category C

FDA Box Warning

• Dinoprostone vaginal suppository should be given only by trained personnel who adhere strictly to recommended dosages, in hospital that can provide immediate intensive care and acute surgical facilities.


Initiates strong contractions of uterine smooth muscle by stimulating myometrium and promoting cervical softening, effacement, and dilation


Endocervical gel: 0.5 mg in 3-g gel vehicle in prefilled syringe with catheter

Vaginal insert: 10 mg

Vaginal suppositories: 20 mg

Indications and dosages

Cervical ripening

Adults: 0.5 mg endocervical gel vaginally; if response is poor, may repeat in 6 hours (not to exceed 1.5 mg in 24 hours). Or one 10-mg vaginal insert.

To induce abortion

Adults: One 20-mg vaginal suppository; repeat q 3 to 5 hours (not to exceed total dosage of 240 mg or duration of 48 hours).

Nonmetastatic gestational trophoblastic disease (benign hydatidiform mole)

Adults: Insert one 20-mg suppository high into vagina; may repeat at 3- to 5-hour intervals for up to 2 days if necessary.


• Hypersensitivity to prostaglandins or additives in gel or suppository

• When vaginal delivery isn't indicated, such as with vasa previa or active genital herpes infection (Prepidil)

• Acute pelvic inflammatory disease

• Ruptured membranes, placenta previa, marked cephalopelvic disproportion, or unexplained vaginal bleeding during pregnancy

• When oxytocics are contraindicated or when prolonged contraction of uterus may be detrimental to fetal safety or uterine integrity, such as with previous cesarean section or major uterine surgery

• Concurrent use of I.V. oxytocics (Cervidil)

• Clinical suspicion or definite evidence of fetal distress when delivery isn't imminent (Cervidil, Prepidil)

• History of difficult labor or traumatic delivery, hyperactive or hypertonic uterine patterns (Prepidil)

• Obstetric emergencies in which benefit-to-risk ratio for either fetus or mother favors surgical intervention (Prepidil)

• Active cardiac, pulmonary, renal, or hepatic disease (Prostin E2 Vaginal Suppository)

• Multipara with six or more previous term pregnancies (Cervidil)

• Grand multipara with six or more previous term pregnancies with non-vertex presentation (Prepidil)


Use cautiously in:

• history of pulmonary, cardiac, renal, or hepatic disease; asthma; jaundice, anemia; cervicitis; infected endocervical lesions; acute vaginitis; compromised (scarred) uterus; hypertension; hypotension; adrenal disorders; diabetes mellitus; epilepsy; glaucoma

• women age 30 or older, those with complications during pregnancy, and those with gestational age of more than 40 weeks are at increased risk of post-partum disseminated intravascular coagulation

• concurrent use of other oxytocics (not recommended).


• Keep patient supine for 15 to 30 minutes after gel administration and for 10 minutes after administering suppository to prevent drug expulsion.

• Store suppositories in freezer; bring to room temperature before using.

Adverse reactions

CNS: headache, drowsiness, syncope

CV: hypotension, hypertension

GI: nausea, vomiting, diarrhea

GU: urinary tract infection, vaginal or uterine pain, uterine contractile abnormalities, warm vaginal sensation, uterine hypertonicity, uterine rupture

Musculoskeletal: back pain

Respiratory: cough, dyspnea, wheezing

Other: allergic reactions including chills, fever, and anaphylaxis


Drug-drug. Other oxytocics: increased oxytocic effects

Patient monitoring

Monitor uterine contractions and observe for excessive vaginal bleeding and cramping. Record sanitary pad count.

• Monitor vital signs and assess for drug-induced fever. Report significant blood pressure and pulse changes.

• Assess for wheezing, chest pain, and dyspnea.

• Evaluate for GI upset. To minimize, give antiemetic before dinoprostone therapy.

Patient teaching

• Advise patient to stay in supine position, as prescribed, after administration.

• Instruct patient to report fever, bleeding, or abdominal cramps.

• Tell patient to avoid douches, tampons, tub baths, and sexual intercourse for at least 2 weeks after receiving drug.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


A PROSTAGLANDIN drug used by injection into the uterus to induce labour. Brand names are Prepidil, Propess-RS and Prostin E2.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
A Cochrane review found that oral misoprostol is as effective as vaginal misoprostol and results in fewer cesarean deliveries than vaginal dinoprostone (Cervidil).
The current study was done with the objective of comparing the efficacy, acceptability and safety of low-dose oral misoprostol tablet (25 ugm PGE1) and intracervical dinoprostone (PGE2) for labour induction and cervical ripening in women at term.
Comparison of vaginal misoprostol and dinoprostone for cervical ripening before diagnostic hysteroscopy in nulliparous women.
Vaginal dinoprostone is the current gold standard method for cervical ripening and induction of labor, although much interest has been generated by the use of misoprostol in induction of labor since 1987, and it has been found to be efficacious and safe [7].
[1,3] A reduced caesarean section rate was reported with the dose of oral misoprostol of 20--25 [micro]g 2-hourly compared with vaginal dinoprostone. [1] Oral misoprostol 50 [micro]g 4-hourly at up to 5 doses was also shown to be as safe and as effective as 25 [micro]g 4-hourly when administered vaginally at 5 doses.
Concurrent Oxytocin in Women Needing Second Dinoprostone. J Coll Physicians Surg Pak.
A cesarean delivery was performed due to failure to respond to induction with dinoprostone and misoprostol.
Marions, "A randomised controlled trial of intravaginal dinoprostone, intravaginal misoprostol and transcervical balloon catheter for labour induction," BJOG: An International Journal of Obstetrics & Gynaecology, vol.
Antioxidants Apoptosis BRCA1 Protein Blotting, Western Cell Adhesion Molecules Cyclobexenes DNA Breaks, Dinoprostone DNA Damage Double-Stranded DNA Repair Enzymes Down-Regulation Potential new Embryonic Escrous Cycle terms here.
Prostaglandin E2 (dinoprostone) kullanimi ile dogumun induklenmesi, artmis UR riski ile iliskili olup, uygun danismanlik sonrasi nadir durumlar disinda kullanilmamasini (Kanit Duzeyi: II-2B); Prostaglandin E1 (misoprostol) UR riskini arttirma ile ileri derecede iliskili oldugunu, SSVD da kullanilmamasi gerektigini (kanit duzeyi: II-2A) ifade etmistir.